Enhertu 100mg (Trastuzumab Deruxtecan) per vial

Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate (ADC) used in the treatment of HER2-positive cancers. Each vial contains 100mg of trastuzumab deruxtecan. Enhertu combines the HER2-targeting properties of trastuzumab with a topoisomerase I inhibitor, deruxtecan, to deliver a potent cytotoxic agent directly to cancer cells.

How It Works

Enhertu works by targeting the HER2 protein, which is overexpressed in certain types of cancer cells. Trastuzumab, the antibody component, binds specifically to the HER2 receptor on the surface of cancer cells. Upon binding, the conjugate is internalized, and the linker is cleaved to release the cytotoxic deruxtecan inside the cell. This causes DNA damage and cell death specifically in HER2-expressing cancer cells, sparing normal cells to a greater extent and reducing systemic toxicity.

Indications

• HER2-positive metastatic breast cancer
• HER2-positive gastric cancer
• HER2-positive non-small cell lung cancer (NSCLC)
• HER2-positive colorectal cancer

Contraindications

• Hypersensitivity to trastuzumab deruxtecan or any component of the formulation
• Pregnancy (due to risk of fetal harm)
• Severe pulmonary impairment
• Severe hepatic impairment

Side Effects

• Nausea
• Vomiting
• Fatigue
• Hair loss
• Decreased appetite
• Diarrhea
• Constipation
• Anemia
• Neutropenia
• Interstitial lung disease (serious and potentially fatal)
• Cardiotoxicity

Price in Different Countries

Top 5 Global Brands

• Enhertu (Daiichi Sankyo and AstraZeneca): The original and primary brand of trastuzumab deruxtecan, used for various HER2-positive cancers.
• Herceptin (Genentech/Roche): The original trastuzumab product, often used in combination therapies for HER2-positive breast cancer.
• Perjeta (Genentech/Roche): Another HER2-targeted therapy, used in combination with Herceptin and chemotherapy for HER2-positive breast cancer.
• Kadcyla (Genentech/Roche): An ADC combining trastuzumab with a microtubule inhibitor, used for HER2-positive breast cancer.
• Phesgo (Genentech/Roche): A combination of pertuzumab, trastuzumab, and hyaluronidase, administered subcutaneously for HER2-positive breast cancer.